These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7780044)

  • 1. Pharmacokinetics of the novel anticonvulsant HEPP after single intravenous administration of three different doses in dogs.
    Gómez LE; Lehmann PA
    Biopharm Drug Dispos; 1995 Mar; 16(2):105-12. PubMed ID: 7780044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose pharmacokinetics of HEPP, a new anticonvulsant in normal healthy volunteers.
    González-Esquivel DF; Rubio-Donnadieu F; Carvajal-Sandoval G; Jung HC
    Biopharm Drug Dispos; 1998 Dec; 19(9):583-7. PubMed ID: 9872340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition kinetics of HEPP in rats after intravenous, oral, and intraperitoneal administration. Correlation of plasma and brain levels with the anticonvulsant effect.
    Gómez LE; Cueva-Rolón R; Lehmann PA
    Biopharm Drug Dispos; 1995 Mar; 16(2):77-89. PubMed ID: 7780049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gestational age dependency in the prenatal toxicity and in the disposition kinetics of the novel anticonvulsant HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) after subcutaneous administration in pregnant rats.
    Gómez-Martínez LE
    Int J Toxicol; 2007; 26(3):237-46. PubMed ID: 17564905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma determination of the novel anticonvulsant D,L-3-hydroxy-3-ethyl-3-phenylpropionamide and preliminary pharmacokinetic studies in the rat.
    Gomez LE; Lehmann PA
    J Chromatogr; 1992 Mar; 575(2):306-10. PubMed ID: 1629310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of HEPP, a new anticonvulsant, in healthy subjects and rabbits after multiple doses.
    González-Esquivel DF; Pérez RM; Cook HJ
    Biopharm Drug Dispos; 2004 Mar; 25(2):85-90. PubMed ID: 14872556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of interaction between HEPP, a new antiepileptic agent, and carbamazepine in rabbits.
    García AL; Medina RL; Pérez MR; Jung CH
    Biopharm Drug Dispos; 2003 Jul; 24(5):205-9. PubMed ID: 12784320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of D,L-3-hydroxy-3-ethyl-3-phenylpropionamide (HEPP) in pregnant rats at different stages of gestation and maternal-fetal disposition during late pregnancy.
    Fletes Mdel R; Gómez-Martínez LE
    Reprod Toxicol; 2003; 17(2):177-84. PubMed ID: 12642150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction in rabbits between a new anticonvulsant, DL-3-hydroxy-3-ethyl-3-phenylpropionamide, and phenytoin.
    Medina L; García L; Pérez R; Fernández A; Jung H
    J Pharm Pharmacol; 1998 Dec; 50(12):1393-6. PubMed ID: 10052855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
    Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
    Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
    Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
    Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients.
    Russo H; Brès J; Duboin MP; Roquefeuil B
    Eur J Clin Pharmacol; 1995; 49(1-2):127-37. PubMed ID: 8751034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog.
    Supko JG; Malspeis L
    Antimicrob Agents Chemother; 1995 Jan; 39(1):9-14. PubMed ID: 7695336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.
    Isoherranen N; Yagen B; Soback S; Roeder M; Schurig V; Bialer M
    Epilepsia; 2001 Jul; 42(7):825-30. PubMed ID: 11488879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and bioavailability of topiramate in the beagle dog.
    Streeter AJ; Stahle PL; Holland ML; Pritchard JF; Takacs AR
    Drug Metab Dispos; 1995 Jan; 23(1):90-3. PubMed ID: 7720530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses.
    Moore SA; Muñana KR; Papich MG; Nettifee-Osborne J
    Am J Vet Res; 2010 Mar; 71(3):337-41. PubMed ID: 20187836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects.
    Ebert U; Thong NQ; Oertel R; Kirch W
    Eur J Clin Pharmacol; 2000 Jul; 56(4):299-304. PubMed ID: 10954343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt and (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu administered intravenously to beagle dogs.
    Tokumura T; Machida R; Tsuchiya Y; Sasaki A; Abe K; Tanaka T; Saeki Y
    J Pharm Sci; 1993 Jul; 82(7):725-8. PubMed ID: 8360847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs.
    Volosov A; Sintov A; Bialer M
    Ther Drug Monit; 1999 Apr; 21(2):219-23. PubMed ID: 10217343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.